ArticleHealth science reports2026
Integrative Bioinformatics Analysis Reveals COL13A1 and COL23A1 as Potential Diagnostic and Prognostic Biomarkers in Thyroid Cancer.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Thyroid cancer, the most prevalent endocrine malignancy globally, poses challenges owing to the limited understanding of its molecular drivers. Previous research has highlighted collagen genes, such as COL13A1 and COL23A1, as key players in thyroid cancer. This study aimed to comprehensively investigate gene expression, genetic alterations, DNA methylation, and the prognostic significance of COL13A1 and COL23A1. Methods: This study employed a multi-omics strategy leveraging the TCGA database and the following resources: TIMER2.0, GEPIA2, UALCAN, HPA, cBioPortal, STRING, Enrichr, Kaplan-Meier Plotter, and R programming. Results: We observed distinct expression patterns for COL13A1 and COL23A1. COL13A1 was significantly upregulated, while COL23A1 was downregulated in tumor tissues compared to normal tissues. Expression levels vary by sample type, tumor stage, and histology, with higher COL13A1 staining intensity and moderate COL23A1 staining observed in tumors. Both decreased COL13A1 and increased COL23A1 expression have been linked to poor prognosis. Promoter methylation levels also differ, showing higher COL23A1 methylation in tumors. SGIP1 and SLC26A4 were identified as the most co-expressed genes. Functional validation using GEO datasets further supported the potential of COL13A1 and COL23A1 as prognostic markers in thyroid cancer. Conclusion: In thyroid cancer, COL13A1 and COL23A1 have emerged as diagnostic and prognostic markers. Co-expression analysis suggests interactions between SGIP1 and SLC26A4, implicating diverse pathways in thyroid carcinogenesis and informing precision medicine strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.